Praxis Precision Medicines, Inc.
NASDAQ:PRAXBiotechnology
+$12.13 today
- Market cap
- $8.53B
- Beta
- 2.75
- P/E (TTM)
- -25.0
- EPS (TTM)
- -$11.31
Volume 0.43M
Average 0.45M
PRAX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Praxis Precision Medicines, Inc.NASDAQ: PRAX
Stock-Based Compensation · Q3 FY2026 · quarter ended Sep 2026
Stock-based compensation growth accelerates
Q3 FY2026 stock-based compensation of $14.89M rose 100.0% year over year, ahead of the -19.6% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 31.7% from the prior quarter. Over 3 fiscal years it compounded at +5.9% a year.
Context
- Stock-based compensation increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +100.0% holds above the trailing-twelve-month pace of -19.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 33.94M USD
- Year-over-year change
- -17.9%
- 4-year CAGR
- +10.6%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 33.94M | -17.9% |
| FY2024 | 2024-12-31 | 41.36M | +66.4% |
| FY2023 | 2023-12-31 | 24.86M | -13.1% |
| FY2022 | 2022-12-31 | 28.59M | +26.0% |
| FY2021 | 2021-12-31 | 22.69M | — |
Stock-Based Compensation vs competitors
How PRAX compares with its peers on the latest reported figures
- PRAX's LTM Sep 2026 stock-based compensation of $26.2M is the 8th largest of the 10 companies compared; the peer median is $59.52M.
- Its year-over-year change of -19.6% is the 9th highest of 10, against a peer median of +15.1%.
- Over three fiscal years its annual growth of +5.9% compares with a peer median of +29.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $235.1M | +4.2% | +8.0% | 6.4% | |
| LTM Jun 2026 | $96.42M | +5.3% | +35.5% | 12.4% | |
| LTM Jun 2026 | $69.95M | +39.2% | -0.1% | 1941.0% | |
| LTM Sep 2026 | $64.29M | +20.9% | +38.1% | — | |
| LTM Jun 2026 | $59.52M | -4.5% | — | 5.2% | |
| LTM Jun 2026 | $58M | +87.8% | +23.4% | 7.0% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $27.96M | -33.3% | +53.3% | — |
| LTM Sep 2026 | $26.2M | -19.6% | +5.9% | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $21.78M | +70.4% | +213.9% | 108.9% |
| LTM Dec 2025 | $10.6M | +15.1% | -14.3% | — | |
| Peer median (excluding PRAX) | $59.52M | +15.1% | +29.4% | 9.7% | |
Competitors are the stored peer set for PRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (167.06M) | (214.03M) | (123.28M) | (182.82M) | (303.27M) |
| Depreciation & Amortization | 182K | 419K | 432K | 358K | 140K |
| Deferred Income Tax | 2.09M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 22.69M | 28.59M | 24.86M | 41.36M | 33.94M |
| Change in Working Capital | 16.13M | (1.78M) | (13.03M) | 10.92M | 22.68M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 7.27M | 3.89M | (8.86M) | 6.71M | 12.1M |
| Other Working Capital | 8.87M | (5.67M) | (4.17M) | 4.21M | 10.58M |
| Other Non-Cash Items | 1.41M | 1.76M | (121K) | (1.58M) | (2.56M) |
| Operating Cash Flow | (124.55M) | (185.04M) | (111.14M) | (131.76M) | (249.07M) |
| Capital Expenditures | (1.05M) | (444K) | (50K) | 0 | (56K) |
| Acquisitions (Net) | 139.47M | (97.33M) | 0 | 0 | 0 |
| Purchases of Investments | (164.17M) | (83.02M) | 0 | (371.52M) | (623.81M) |
| Sales of Investments | 24.7M | 180.36M | 39M | 123.03M | 312.72M |
| Other Investing Activities | (139.47M) | 97.33M | 0 | 0 | 0 |
| Investing Cash Flow | (140.52M) | 96.89M | 38.95M | (248.49M) | (311.15M) |
| Debt Repayment | (763K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 105.71M | 9.56M | 91.59M | 512M | 704.26M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.64M | 904K | 279K | 2.33M | (2.09M) |
| Financing Cash Flow | 107.59M | 10.47M | 91.87M | 514.32M | 702.17M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (157.49M) | (77.69M) | 19.69M | 134.07M | 141.96M |
| Free Cash Flow | (125.6M) | (185.49M) | (111.19M) | (131.76M) | (249.12M) |
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
Intrinsic Alpha fair value
Locked
Current Price
$305.19
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.